Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

BACKGROUND: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. CASE: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Max Philipp Hartwich, Tobias, Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265468/
https://www.ncbi.nlm.nih.gov/pubmed/37325296
http://dx.doi.org/10.1016/j.gore.2023.101218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265468/
https://www.ncbi.nlm.nih.gov/pubmed/37325296
http://dx.doi.org/10.1016/j.gore.2023.101218

Ejemplares similares